van de WielPA, van der PijlA, BloksmaN.Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity. Cancer Immunol Immunother1991;33:115–120.
2.
DigheAS, RichardsE, OldLJ, SchreiberRD.Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity1994;1:447–456.
3.
BlondiauC, LagadecP, LejeuneP, OnierN, CavaillonJM, JeanninJF.Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiology1994;190:243–254.
4.
InagawaH, NishizawaT, HondaT, NakamotoT, TakagiK, SomaG.Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: Involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res1998;18(5D):3957–3964.
5.
InagawaH, NishizawaT, TakagiK, GotoS, SomaG, MizunoD.Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res1997;17(3C):1961–1964.
6.
ShimizuT, IidaK, IwamotoY, YanagiharaY, RyoyamaK, AsaharaT, IkedaK, AchiwaK.Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol1995;17:425–431.
7.
OnierN, LejeuneP, MartinM, HammannA, BauerJ, HirtP, LagadecP, JeanninJF.Involvement of T lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases. Eur J Cancer1993;29A:2003–2009.
8.
OnierN, HilpertS, ArnouldL, Saint-GiorgioV, DaviesJG, JeanninJF, JeanninJF. Cure of colon cancer metastasis in rats with the new lipid A OM 174: Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis1999;17:299–306.
9.
LagadecP, RaynalS, LieubeauB, OnierN, ArnouldL, Saint-GiorgioV, LawrenceDA, JeanninJF.Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells: Implications for tumor development. Am J Pathol1999;154:1867–1876.
10.
ColeyWB.The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and bacillus prodigiosus. J Am Med Assoc1898;31:589–595.
11.
ShearMJ, TurnerFC.Chemical treatment of tumors: V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst1943;4:81–97.
12.
ParrI, WheelerE, AlexanderP.Similarities of the anti-tumor actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer1973;27:370–389.
13.
ReisserD, PanceA, JeanninJF.Mechanisms of the antitumoral effect of lipid A. Bioessays2002;24:284–289.
14.
MatsumotoN, OidaH, AzeY, AkimotoA, FujitaT.Intratumoral necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog. Anticancer Res1998;18(6A):4283–4289.
15.
JeanninJF, OnierN, LagadecP, VonJeney N,StützP, LiehlE.Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology1991;101:726–733.
16.
JimboT, AkimotoT, TohgoA.Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits. Anticancer Res1996;16:359–364.
17.
MizushimaY, SassaK, FujishitaT, OosakiR, KobayashiM.Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats. J Immunother1999;22:401–406.
18.
AkimotoT, KumazawaE, JimboT, JotoN, TohgoA.DT-5461a, an antitumor synthetic lipid a analog, causes selective blood flow reduction in tumor tissue. Anticancer Res1995;15:105–107.
19.
MatsushitaK, KobayashiM, TotsukaY, HosokawaM.ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-α. Anticancer Drugs1998;9:273–282.
20.
OnierN, HilpertS, ReveneauS, ArnouldL, Saint-GiorgioV, ExbrayatJM, JeanninJF.Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int J Cancer1999;81:755–760.
21.
VosikaGJ, BarrC, GilbertsonD.Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother1984;18:107–112.
22.
KianiA, TschierschA, GaboriauE, OttoF, SeizA, KnopfHP, StützP, FärberL, HausU, GalanosC, MertelsmannR, EngelhardtR.Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood1997;90:1673–1683.
23.
de BonoJS, DalgleishAG, CarmichaelJ, DiffleyJ, LoftsFJ, FyffeD, EllardS, GordonRJ, BrindleyCJ, EvansTR.Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res2000;6:397–405.
24.
FungPY, MadejM, KogantyRR, LongeneckerBM.Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res1990;50:4308–4314.
25.
OgawaT, NakazawaM, MasuiK.Immunopharmacological activities of the nontoxic monophosphoryl lipid A of Porphyromonas gingivalis. Vaccine1996;14:70–76.
26.
MitchellMS, Kan-MitchellJ, KempfRA, HarelW, ShauHY, LindS.Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res1988;48:5883–5893.
27.
MitchellMS, HarelW, Kan-MitchellJ, LeMayLG, GoedegebuureP, HuangXQ, HofmanF, GroshenS.Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci1993;690:153–166.
28.
ElliottGT, McLeodRA, PerezJ, Von EschenKB.Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol1993;9:264–272.
29.
EtonO, KharkevitchDD, GiananMA, RossMI, ItohK, PrideMW, DonawhoC, BuzaidAC, MansfieldPF, LeeJE, LeghaSS, PlagerC, PapadopoulosNE, BedikianAY, BenjaminRS, BalchCM.Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res1998;4:619–627.
30.
HellingF, ZhangS, ShangA, AdluriS, CalvesM, KogantyR, LongeneckerBM, YaoTJ, OettgenHF, LivingstonPO.GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res1995;55:2783–2788.
31.
SchultzN, OratzR, ChenD, Zeleniuch-JacquotteA, AbelesG, BystrynJC.Effect of Detox as an adjuvant for melanoma vaccine. Vaccine1995;13:503–508.
32.
O/BoyleKP, ZamoreR, AdluriS, CohenA, KemenyN, WeltS, LloydKO, OettgenHF, OldLJ, LivingstonPO.Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res1992;52:5663–5667.
33.
AdluriS, HellingF, OgataS, ZhangS, ItzkowitzSH, LloydKO, LivingstonPO.Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother1995;41:185–192.
34.
MacLeanGD, ReddishM, KogantyRR, WongT, GandhiS, SmolenskiM, SamuelJ, NabholtzJM, LongeneckerBM.Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother1993;36:215–222.
35.
LongeneckerBM, ReddishM, KogantyR, MacLeanGD.Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann N Y Acad Sci1993;690:276–291.
36.
LongeneckerBM, ReddishM, KogantyR, MacLeanGD.Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis. Adv Exp Med Biol1994;353:105–124.
37.
MilesDW, TowlsonKE, GrahamR, ReddishM, LongeneckerBM, Taylor-PapadimitriouJ,RubensRD.A randomised Phase II study of sialyl-Tn and Detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer1996;74:1292–1296.
38.
MacLeanGD, ReddishMA, KogantyRR, LongeneckerBM.Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol1996;19:59–68.
39.
MacLeanGD, MilesDW, RubensRD, ReddishMA, LongeneckerBM.Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol1996;19:309–316.
40.
ReddishMA, MacLeanGD, PoppemaS, BergA, LongeneckerBM.Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother1996;42:303–309.
41.
MacLeanGD, ReddishMA, LongeneckerBM.Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother1997;20:70–78.
42.
ReddishM, MacLeanGD, KogantyRR, Kan-MitchellJ, JonesV, MitchellMS, LongeneckerBM.Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer1998;76:817–823.
43.
SandmaierBM, OparinDV, HolmbergLA, ReddishMA, MacLeanGD, LongeneckerBM.Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother1999;22:54–66.
44.
HolmbergLA, OparinDV, GooleyT, LillebyK, BensingerW, ReddishMA, MacLeanGD, LongeneckerBM, SandmaierBM.Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and Theratope STn-KLH cancer vaccine. Bone Marrow Transplant2000;25:1233–1241.
45.
WoodlockTJ, SahasrabudheDM, MarquisDM, GreeneD, PandyaKJ, McCuneCS.Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 α. J Immunother1999;22:251–259.
46.
KhleifSN, AbramsSI, HamiltonJM, Bergmann-LeitnerE, ChenA, BastianA, BernsteinS, ChungY, AllegraCJ, SchlomJ. A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother1999;22:155–165.
47.
HarrisDT, MatyasGR, GomellaLG, TalorE, WinshipMD, SpitlerLE, MastrangeloMJ.Immunologic approaches to the treatment of prostate cancer. Semin Oncol1999;26:439–447.
48.
MeidenbauerN, HarrisDT, SpitlerLE, WhitesideTL.Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate2000;43:88–100.
